Insights on Patient-Focused Drug Development (PFDD) OUR INSIGHTS LEARN MORE Contact Us We share our insights to keep you updated on patient engagement initiatives, trends, and regulatory guidelines Down arrow icon

OUR INSIGHTS

Online trial investigator result meetings - what about the investigators’ feedback?
Laura Lassen
Posted by Laura Lassen
January 22, 2021

Online trial investigator result meetings - what about the investigators’ feedback?

Following the outbreak of the COVID-19 pandemic, we now see that investigator result meetings have changed their format to online interaction...

Read More
Generating early insights on investigational drug
Jens Harald Kongsø
Posted by Jens Harald Kongsø
January 7, 2021

The value of generating early insights on your investigational drug

When pharmaceutical companies develop new medicines, they are required to comply with regulatory requirements by reporting and publishing their clinical results. Adhering to these...

Read More
Informing trial patients on the clinical trial results
Laura Lassen
Posted by Laura Lassen
December 30, 2020

Are you properly informing your trial patients on the clinical trial results?

The importance of keeping your trial patients well-informed. True patient-centricity is not only obtaining input from trial patients – it also involves ...

Read More
Patient and Public Involvement (PPI)
Laura Lassen
Posted by Laura Lassen
December 18, 2020

Initiatives facilitating the advancement of Patient and Public Involvement in drug development

Patient and Public Involvement (PPI) can improve clinical research success. PPI is defined as research that is carried out with or by patients and those who have experience of a condition...

Read More
Patient feedback
Laura Lassen
Posted by Laura Lassen
December 11, 2020

Consequences of not listening to the patients in clinical trials

Are you overlooking patient feedback on your investigational drug? Interestingly, the pharmaceutical industry is one of the few industries where...

Read More
Patient preferences as input to drug development
Laura Lassen
Posted by Laura Lassen
December 4, 2020

Patient preferences as input to medical product decision making

PREFER’s patient input to decision making under evaluation by EMA and EUnetHTA. At Clinigma®, we are always happy to follow the development of projects promoting patient engagement...

Read More